Actinium to work with Astellas Pharma on its AWE Platform Technology

Actinium Pharmaceuticals and Astellas Pharma will work together to develop Actinium-225 Radio-Conjugates (ARCs) using Actinium Warhead Enabling (AWE) Platform Technology, the USA-based company said Wednesday.Actinium said that under this collaboration, it will use AWE Platform to conjugate and label selected Astellas targeting agents with the powerful actinium-225 (225Ac) payload. Actinium also said it will be conducting preclinical validation studies on the novel ARCs generated.

Actinium didn’t precise the financial side of it, but it said it would receive a seven-digit payment which includes upfront fee and research funding from Astellas.

Dr. Dale Ludwig, Actinium’s Chief Scientific Officer said the collaboration further shows the value of Actinium’s AWE technology by enabling biomolecules with the potent cell killing power of 225Ac.

“Our AWE Platform introduces a novel and complementary mechanism of action which is supported by significant preclinical and clinical data. We are well positioned to execute on this exciting collaboration and look forward to advancing the field of Actinium-225 Radio-Conjugates through this collaboration with Astellas,” Actinium’s scientific boss said.